CorMatrix Cardiovascular Receives Core U.S. Patent For Injectable Biomaterial

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ATLANTA--(BUSINESS WIRE)--CorMatrix® Cardiovascular, Inc., (www.cormatrix.com) a leading medical device developer, today announced the issuance of U.S. Patent No. 8,568,761 for an augmented injectable extracellular matrix (ECM®) bioscaffold. The augmented ECM® bioscaffold induces stem cell proliferation and differentiation of stem cells into cardiomyocytes, and, thereby, angiogenesis and remodeling, i.e. tissue repair, of cardiovascular tissue.

Help employers find you! Check out all the jobs and post your resume.